Related Experiment Video
Updated: Jul 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation
Cristina Gervasoni1, Ottavia Vigano, Erika Grinelli
1Clinical Science Department, Section of Infectious Diseases, University of Milan, L Sacco Hospital, Via GB Grassi 74 20157 Milan, Italy. cristina.gervasoni@unimi.it.
Abstract:
A 36-year-old man with HIV infection developed a reaction compatible with an abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. The switch was determined by a more convenient intake. The patient was treated with abacavir twice-daily plus lamivudine and efavirenz for more than 5 years with no side effects. At the time of this change, his CD4 count was 1069 cell/mm(3) and HIV-RNA undetectable. Our case suggests that patients should be carefully monitored after switching, and warned about the potential effects.
Related Concept Videos
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Allergic Drug Reactions
Drug Toxicity: Allergic Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Hypersensitivity Reactions: Immune-Complex Reactions
Drug toxicity: Idiosyncratic Reactions